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ABSTRACT
Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is 
common. We found that reactivation of EGFR, HER2 and HER3 occurred within 24 
hours of lapatinib treatment after their initial dephosphorylation. This was associated 
with increased expression of NRG1 in cells treated with lapatinib. Exogenous NRG1 
partially rescued breast cancer cells from growth inhibition by lapatinib. In addition, 
both parental and lapatinib-resistant breast cancer cells were sensitive to SGP1, which 
inhibits binding of NRG1 and other HER3 ligands. Addition of pertuzumab to lapatinib 
further inhibited NRG1-induced signalling, which was not fully inhibited by either 
drug alone. In animal model, a combination of pertuzumab to lapatinib induced a 
greater tumor regression than either lapatinib or pertuzumab monotherapy. This novel 
combination treatment may provide a promising strategy in clinical HER2-targeted 
therapy and may inhibit a subset of lapatinib-resistant breast cancer, although the 
group of patients that will respond to this therapy requires further stratification.  
INTRODUCTION
The human epidermal growth factor receptor 
(HER, also known as ErbB) family consists of four 
transmembrane receptor tyrosine kinases, EGFR, 
HER2, HER3 and HER4 [1]. Dysregulation of the 
HER signalling pathway has been implicated in various 
epithelial cancers; for example, breast cancer, head and 
neck, and lung cancers [2]. Overexpression of HER2 
protein and/or amplification of the HER2 gene occurs in 
around 20% of breast cancer patients and correlates with 
adverse prognosis and poor clinical outcome [3, 4]. HER2 
overexpression correlates with tumour size, lymph node 
positivity, high tumour grade and aneuploidy [5]. There 
are two main types of HER2-targeted therapy: monoclonal 
antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) 
[3]. Trastuzumab, pertuzumab (mAbs), trastuzumab 
emtansine (T-DM1, an antibody-drug conjugate) and 
lapatinib (TKI) were approved by the U.S. Food and Drug 
Administration and the European Medicines Agency and 
are now used in HER2-positive breast cancer patients. 
Trastuzumab is also used in HER2-positive gastric 
patients.
Pertuzumab is a humanised mAb that binds to the 
dimerisation domain (subdomain II) of the extracellular 
region of HER2, preventing its dimerisation with other 
HER receptors and thus inhibiting the HER signalling 
pathway [6, 7]. In preclinical studies, pertuzumab 
was found to inhibit NRG1-induced growth [8] and 
morphogenesis in vitro, and trigger rapid tumour 
regression in NRG1-dependent xenograft model [9]. The 
combination of pertuzumab and trastuzumab was shown 
to be synergistic in inhibiting the survival of HER2-
overexpressing breast cancer cell line BT-474 [10]. In 
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conjunction with chemotherapy, this combination has 
been shown to prolong PFS compared to trastuzumab 
in metastatic breast cancer as first line treatment [11] 
and improve pathological complete response (pCR) 
when used as a neoadjuvant therapy in early breast 
cancer [12]. Therefore, the FDA has approved the use 
of the combination of pertuzumab and trastuzumab with 
chemotherapy in metastatic breast cancer and early HER2-
overexpressing breast cancer in the neoadjuvant setting.
Lapatinib is a small molecule chemical inhibitor 
designed to target the tyrosine kinase domain (TKD) of 
EGFR and HER2 [13, 14]. Lapatinib reversibly binds 
to the ATP-binding pocket of the TKD and prevents 
phosphorylation [14]. It has been proven successful in 
inhibiting the phosphorylation of HER receptors and its 
downstream targets such as Akt and MAPK [14, 15], 
and slowing down tumour growth in vitro and in vivo 
[13, 14]. Lapatinib is used in patients with advanced 
HER2-positive breast cancer that have progressed 
after previous trastuzumab containing regimens and its 
efficacy as a single targeted therapy with chemotherapy 
has been shown [16, 17]. Lapatinib in combination with 
trastuzumab and chemotherapy has been reviewed in 
neoadjuvant studies such as CHER-LOB [18], NSABP 
B-41 [19] and neoALTTO trials [20]. Recently, a meta-
analysis of six randomised trials had concluded that 
lapatinib in combination with chemotherapy achieved 
a lower pCR and higher risk of toxicity compared to 
trastuzumab with chemotherapy in the neoadjuvant 
setting [21]. Furthermore, a phase III study reported in 
the 2012 American Society of Clinical Oncology Annual 
Meeting found that, metastatic HER2-positive breast 
cancer patients who received lapatinib and chemotherapy 
had shorter PFS than those receiving trastuzumab and 
chemotherapy [22].
Several models have been proposed to explain 
the resistance to lapatinib in HER2-overexpressing 
breast cancer. Lapatinib derepresses FOXO3a, which 
stimulates oestrogen receptor (ER) transcription and leads 
to the co-dependence on ER and HER2 signalling [23]. 
Lapatinib activates ER-induced overexpression of AXL, 
which stimulates downstream PI3K/Akt pathway and 
promotes survival [24]. Derepression of FOXO3a also 
upregulates HER3 [25]. Lapatinib triggers a calcium stress 
response that activates RelA, which inhibits apoptosis 
[26]. Recently, Xia et al. reported that NRG1 autocrine 
stimulation of EGFR/HER3 signalling mediates acquired 
lapatinib resistance [27], although the exact mechanism 
was not elucidated.
Here, we report that NRG1 stimulation activated 
HER3 and HER4 signalling despite the inhibition incurred 
by lapatinib. However, a novel combination of HER2-
targeted therapies, lapatinib and pertuzumab, inhibited 
these NRG1-stimulated HER signalling pathways. The 
anti-tumour activity of this drug combination was verified 
in vitro and in vivo and was confirmed to be more efficient 
than either drug alone.
RESULTS
Lapatinib could not sustain the inhibition of 
HER receptor signalling and upregulates NRG1 
expression
To assess the acute response that may counteract 
lapatinib inhibition, we treated two commonly used 
HER2-overexpressing breast cancer cell lines, SK-BR-3 
and BT-474, with lapatinib for 24 hours. After 4 hours of 
lapatinib treatment, the phosphorylation of EGFR, HER2 
and HER3 in both cell lines was reduced. However, these 
receptors started to rephosphorylate after 8 to 24 hours 
whilst on treatment (Fig. 1A and B). In SK-BR-3 cells, 
the phosphorylation of downstream effectors of the HER 
signalling pathway, MAPK and Akt, were inhibited 
by lapatinib after 1 hour, but started to recover after 24 
hours of lapatinib treatment (Fig. 1A). In BT-474 cells, 
the dephosphorylation and reactivation of Akt correlated 
with its upstream HER3 receptor in a similar way to 
SK-BR-3, but it was more robust and rapid in BT-474. 
However, phospho-MAPK followed a different pattern 
(Fig. 1B). The phosphorylation of MAPK decreased to an 
undetectable level after 1 hour of treatment; however, it 
rose to near basal level at 4 hours and decreased again 
from 8 to 24 hours. 
Xia et al. (2013) reported a model of acquired 
lapatinib resistance, in which EGFR/HER3 signalling was 
induced by NRG1 autocrine stimulation [27]. However, 
the short-term effect of lapatinib on NRG1 expression 
was not shown. We hypothesised that the reactivation 
of EGFR, HER2 and HER3 as well as the downstream 
pathways during the first 24 hours of lapatinib treatment 
could be mediated by NRG1. We showed that lapatinib 
treatment in 100 nM and 250 nM for 8 hours induced 
an increasing trend of NRG1 mRNA expression in SK-
BR-3 cells (Fig. 1C), although the increase was not 
statistically significant. In BT-474 cells, NRG1 mRNA 
level increased significantly after the cells were treated 
with 250 nM lapatinib for 8 hours (p<0.05) but not with 
100 nM lapatinib (Fig. 1D). We further confirmed that 
there was a small but statistically significant increase in 
NRG1 protein expression upon lapatinib treatment using 
ELISA. In SK-BR-3 and BT-474 cells, both 100 nM and 
250 nM lapatinib increased NRG1 expression in the cell 
lysates (Fig. 1E and F, all p <0.0001 compared to DMSO). 
However, NRG1 level in the medium was too low to be 
detected by ELISA (data not shown).
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Acquired lapatinib resistance is mediated by 
HER3 ligands
Since NRG1 level was shown to be increased 
during the first 8 hours of lapatinib treatment (Figure 1E 
and F) and it has also been shown to mediate acquired 
lapatinib resistance [27], we assessed the effect of HER3 
monoclonal antibody, SGP1, that could block HER3 
ligands from binding the receptors [28] in both parental 
and lapatinib-resistant SK-BR-3 and BT-474 cells. SGP1 
alone or lapatinib alone reduced the cell number of the 
parental SK-BR-3 and BT-474 cells significantly (both 
p<0.001 compared to the control) (Fig. 2A and B). The 
addition of SGP1 to lapatinib was more effective than 
lapatinib alone in the parental BT-474 cells and not SK-
BR-3 cells, although this was not more effective than 
SGP1 alone in BT-474 cells (Fig. 2A and B). We generated 
lapatinib-resistant cell lines from HER2-overexpressing 
breast cancer cell lines SK-BR-3 and BT-474 by chronic 
lapatinib treatment up to the concentration of 250 nM over 
10 months. The resistant cell lines had reduced sensitivity 
to lapatinib treatment (Suppl. Fig. 1). In the resistant 
cells, there was an increase of cell number when lapatinib 
was withdrawn in BT250LR cells (Fig. 2D) but not in 
Figure 1: Reactivation of HER receptors occurs within 24 hours of lapatinib treatment, correlating with an increase in 
NRG1 expression. (A) SK-BR-3 and (B) BT-474 cells were treated with 100 nM lapatinib for the indicated times or DMSO solvent control 
before immunoblotting for the indicated proteins. β-actin blot served as loading control in all experiments. Reproducible representative 
results of at least three independent experiments are shown. (C) SK-BR-3 and (D) BT-474 cells were treated with the indicated doses of 
lapatinib or DMSO control for 8 hours. The mRNA expression of NRG1 was assessed by qPCR and the relative expression level of NRG1 
with respect to β-actin control was calculated using the dCt method. Three independent experiments were performed in three technical 
replicates each time. (E) SK-BR-3 and (F) BT-474 cells were treated with the indicated concentrations of lapatinib or DMSO control for 
8 hours. Equal amount of complete cell lysates were applied to NRG1 ELISA kit according to manufacturer protocol. Three independent 
experiments were performed with two technical replicates for ELISA. (Error = SD; *p<0.05, **p<0.01, ****p<0.0001).
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SK250LR cells (Fig. 2C). SGP1 with or without lapatinib 
withdrawal could reduce the cell number significantly in 
both resistant cells (Fig. 2C and D). Thus, we showed that 
both parental and resistant SK-BR-3 and BT474 cells were 
sensitive to SGP1, which inhibits binding of NRG1 and 
other HER3 ligands.
Exogenous NRG1 stimulation induces acquired 
resistance to lapatinib
To further confirm the role of NRG1 in mediating 
resistance to lapatinib, we stimulated SK-BR-3 and 
BT-474 cell with exogenous NRG1, while they were 
concurrently treated with lapatinib. In both cell lines, 
lapatinib decreased the cell number significantly 
(p<0.0001 compared to DMSO in both cell lines), but the 
addition of NRG1 to lapatinib treatment recovered the 
cell number to the control level (p<0.0001 compared to 
lapatinib alone in both cell lines) (Suppl. Fig. 2A and B). 
The above results provided evidence that NRG1, a HER3 
ligand, rescues HER2-overexpressing cell lines SK-BR-3 
and BT-474 cells from the inhibitory effect of lapatinib.
Combination of lapatinib and pertuzumab 
inhibits NRG1-induced signalling
Although NRG1 autocrine signalling was proposed 
to be one of the underlying mechanisms of lapatinib 
Figure 2: The inhibitory effect of lapatinib and/or SGP1 on cell growth in parental and lapatinib-resistant HER2-over-
expressing breast cancer cells. (A) SK-BR-3 and (B) BT-474 cells were treated with the indicated agents for 3 days. (C) SK250LR 
and (D) BT250LR cells were seeded and maintained in continuous lapatinib treatment the night before the experiment. On the next day, the 
drug was taken off and the indicated agents were applied for 3 three days. The cells were then trypsinised and counted. The percentage cell 
number was normalised to ( A and B) the untreated control or (C and D) continuous 250nM lapatinib plus 20 μg/ml non-specific IgG control. 
At least three independent experiments were done with three technical replicates. (Error = SD; **p<0.01, ***p<0.001, ****p<0.0001).
Oncotarget5682www.impactjournals.com/oncotarget
resistance, no effective treatment option has been 
proposed [27]. NRG1 is a ligand for HER3 and HER4, 
and the release of NRG1 and other HER ligands could 
induce HER2 dimerisation with other HER receptors [1]. 
This is supported by a report that lapatinib could increase 
HER2/HER3 and EGFR/HER2 dimerisation [29]. Thus, 
we hypothesised that the HER2 dimerisation inhibitor, 
pertuzumab, could inhibit NRG1-mediated HER receptor 
signalling induced by lapatinib treatment [30].
In serum-free media, lapatinib inhibited 
phosphorylation of all HER receptors and the downstream 
Akt and MAPK in both parental cell lines (Fig. 3A and B). 
Figure 3: The effect of the lapatinib/pertuzumab combination on NRG-1 stimulated HER signalling, cell growth and 
viability. (A) SK-BR-3 and (B) BT-474 cells were grown in serum-free culture media for 24 hours before being treated with 100 nM 
lapatinib and/or 20 μg/ml pertuzumab for 1 hour. DMSO and/or 20 μg/ml non-specific IgG were used as treatment controls. In the last 
10 minutes of treatment, 10 ng/ml NRG1 was added as indicated before immunoblotting for the indicated proteins. β-actin blot served as 
loading control in all experiments. Reproducible representative results of at least three independent experiments are shown. None of the 
two commercially available anti-HER4 antibodies produced convincing bands in western blot (data not shown). (C) SK-BR-3 and (D) BT-
474 cells were treated with the indicated doses of lapatinib or DMSO control, and 20 μg/ml pertuzumab or non-specific human IgG control 
before the cells were trypsinised and counted. Cell number were normalised with DMSO and IgG control. Three independent experiments 
were done with three technical replicates. Three independent experiments were performed with three technical replicates. (Error = SD; 
***p<0.001, ****p<0.0001).
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When the cells were stimulated by NRG1, lapatinib could 
still inhibit phosphorylation of EGFR and HER2; however, 
there was an increase in phosphorylation of HER3, HER4, 
MAPK and Akt compared to lapatinib alone. These results 
suggested that NRG1 stimulation could partially reverse 
the inhibition induced by lapatinib. We showed that 
pertuzumab alone did not inhibit any HER receptors nor 
downstream targets analysed in both SK-BR-3 and BT-
474 cells; however, in the presence of NRG1 stimulation, 
pertuzumab inhibited phospho-EGFR, phospho-HER2 and 
phospho-HER4 (Fig. 3A and B). This result indicated that 
pertuzumab inhibited as well as decreased NRG1-induced 
HER3 activation ligand-induced HER signalling in these 
cells.
When the cells were stimulated by NRG1, the 
combination of lapatinib and pertuzumab inhibited 
phospho-HER3, phospho-HER4, phospho-Akt and 
phospho-MAPK more than lapatinib alone. Both 
phospho-HER3 and phospho-HER4 were inhibited to 
levels comparable to no NRG1 stimulation in SK-BR-3 
cells (Fig. 3A). Phospho-Akt and phospho-MAPK in SK-
BR-3 cells were still higher than basal levels when NRG1-
stimulated cells were treated with the combination (Fig. 
3A); however, in BT-474 cells, both downstream effectors 
were completely inhibited (Fig. 3B). This experiment 
showed that the combination of lapatinib and pertuzumab 
could inhibit NRG1-stimulated HER signalling pathways, 
which were not completely inhibited by either drug alone.
Effect of the combination of lapatinib and 
pertuzumab in vitro
The additive effect of the combination of lapatinib 
and pertuzumab on the inhibition of NRG1-stimulated 
HER signalling suggested that this combination might 
Figure 4: Effect of pertuzumab with or without continuous lapatinib treatment in lapatinib-resistant cell lines. (A) 
SK250LR and (B) BT250LR cells were seeded and maintained in continuous lapatinib treatment the night before the experiment. On the 
next day, the drug was taken off before being treated with the indicated treatments for 3 days. Cells were then trypsinised and counted. 
The percentage cell number was normalised with continuous 250nM lapatinib/non-specific IgG. Three independent experiments with three 
technical replicates were performed. (C) SK250LR and (D) BT250LR cells were treated with the indicated treatment for 2 days. Cells were 
then trypsinised, collected and stained with Annexin V-Alexa Fluor 647 and propidium iodide. Stained cells were analysed using CyAn 
FACS analyser. Three independent experiments were performed.  (Error = SD; *p<0.05, **p<0.01, ****p<0.0001).
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have improved anti-tumour activity. In total cell counting 
experiments, the combination of lapatinib and pertuzumab 
(blue line) was shown to reduce total cell number more 
than lapatinib alone at any concentration (red line) and 
pertuzumab alone (green dashed line) in both SK-BR-3 
and BT-474 cells (Fig. 3C and D). The difference between 
the combination and lapatinib alone was significant in 
both SK-BR-3 (p<0.001) and BT-474 (p<0.0001) cells, 
suggesting the combination effect of the two drugs may 
be additive.
The additive effect of the drug combination was 
further confirmed by an apoptotic assay. Although the 
combination of lapatinib and pertuzumab induced the 
highest percentage of apoptotic cells in both cell lines, 
the change was only statistically significant compared to 
lapatinib alone (+IgG control) in BT474 but not SK-BR-3 
cells (Suppl. Fig. 3A and B and Suppl. Fig. 4). However, 
the combination was significantly more effective than 
pertuzumab alone in both cell lines. In order to further 
understand the differences between the two cell lines, the 
effect of the drug combination was investigated in the 
lapatinib-resistant cell lines as below.
Effect of the combination of lapatinib and 
pertuzumab in lapatinib-resistant cell lines
The drug combination was tested on lapatinib-
resistant cell lines SK250LR and BT250LR to understand 
whether this could overcome acquired lapatinib resistance. 
Figure 5: Effect of lapatinib withdrawal from lapatinib-resistant cell lines on their HER signalling profile and lapatinib 
sensitivity. (A) SK250LR and (B) BT250LR cells were continuously treated with 250 nM lapatinib or had the drug withdrawn for 7 days 
before being immunoblotted for the indicated proteins. Reproducible representative results of at least three independent experiments are 
shown. (C) SK250LR and (D) BT250LR were either continuously treated with 250 nM lapatinib treatment (solid bars, Cont) or had 
withdrawal of the drug (hollow bars, 7DW) for 7 days before they were re-seeded to 24-well plates. Cells were then treated with DMSO 
or 250 nM lapatinib for 3 days, and then trypsinised and counted. The percentage of cell number was normalised to the cells treated with 
lapatinib continuously and then no drug for 3 days (Cont-No drug). Three independent experiments were performed with three technical 
replicates. (Error = SD; ****p<0.0001).
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Pertuzumab slightly reduced cell number (p<0.01) 
compared to the DMSO (+ IgG control) only when 
lapatinib was withdrawn in SK250LR cells but there was 
no statistically significant difference between all other 
groups (Fig. 4A), indicating that pertuzumab was not very 
effective in SK250LR cells. This is consistent with the 
apoptotic assay, which showed that pertuzumab did not 
cause any change in the percentage of apoptotic cells with 
or without lapatinib in SK250LR cells (Fig. 4C and Suppl. 
Fig. 5A to F). In BT250LR cells, withdrawal of lapatinib 
resulted in a statistically significant higher number of 
cell count compared to those with continuous lapatinib 
treatment (p<0.0001, Fig. 4B). Pertuzumab significantly 
reduced cell number of BT250LR whether or not lapatinib 
was present (both p<0.0001), which is consistent with 
the apoptotic assay (Fig 4D, Suppl. Fig. 5G to L). These 
experiments showed that lapatinib-resistant cell line 
BT250LR was sensitive to pertuzumab with or without 
continuous lapatinib treatment, but not SK250LR.
Lapatinib-resistant SK-BR-3 lost its dependence 
on HER2 signalling pathway
In previous experiments, the resistant cells were 
continuously treated with lapatinib until being seeded 
for cell counting experiments. To investigate the reasons 
for SK250LR cell line not responding to the combined 
anti-HER2-targeted therapy, lapatinib was removed from 
the lapatinib-resistant cell lines for 7 days (7D) before 
further western blot and cell counting experiments. The 
HER signalling profile of these 7D-lapatinib-withdrawn 
cells was compared to cells that were continuously treated 
with lapatinib and untreated parental cells. In SK250LR 
cells, phospho-EGFR, phospho-HER2 and phospho-
HER4 did not reactivate after lapatinib was removed for 
7 days (Fig. 5A). Furthermore, the expression levels of 
EGFR and HER2 decreased after 7D-lapatinib withdrawal, 
indicating that the cells might have developed permanent 
changes in the cell biology, in which they were no longer 
dependent on EGFR and HER2 signalling. In fact, the cell 
counting experiments revealed that SK250LR cells were 
still insensitive to lapatinib even after 7 days of lapatinib 
withdrawal (Fig. 5C). HER3 and Akt were slightly 
rephosphorylated (Fig 5A). They appeared to correlate 
with each other, as Akt is the main downstream effector 
of HER3. Phospho-MAPK significantly increased in 
SK250LR cells after 7D-lapatinib withdrawal; however, 
this change was not correlated to the phosphorylation any 
of the HER receptors.
In BT250LR cells, all the HER receptors and 
downstream proteins rephosphorylated after lapatinib 
was removed for 7 days (Fig. 5B). The levels of phospho-
EGFR, phospho-HER2, phospho-HER4 and phospho-Akt 
in BT250LR after 7-day withdrawal were even higher 
than those in untreated BT-474 cells. Phospho-HER3 
recovered to similar level of untreated BT-474 cells, but 
phospho-MAPK was still below the basal level. There was 
no difference in the expression levels of EGFR, HER2 
and HER3 before and after 7D-lapatinib withdrawal. 
The reintroduction of 250 nM lapatinib after 7 days of 
withdrawal (7DW-250 nM Lap) caused a decrease in the 
cell number of BT250LR cells-7DW compared to DMSO 
control (p<0.0001), which was more than those which 
were continuously treated with lapatinib (Cont-250 nM 
Lap) (Fig. 5D). This indicates that the cells were only 
transiently adapted to lapatinib, and removing lapatinib 
from BT250LR cell line reverted its resistance resulting 
in BT250LR-7DW becoming more sensitive to lapatinib.
By comparing the differences in HER signalling 
profile between SK250LR and BT250LR cell lines, it is 
suggested that BT250LR cells responded to pertuzumab 
treatment because they were still dependent on the HER2 
signalling, whilst SK250LR cells had downregulation of 
HER2 and decreased pHER2 levels, suggesting a shift of 
dependency from HER2 signalling and hence being less 
sensitive to pertuzumab.
Effect of the combination of lapatinib and 
pertuzumab in vivo
The anti-tumour efficacy of the drug combination 
was further tested in a BT-474 mouse xenograft model. In 
the clinical setting, a lower dose of lapatinib has been used 
when combined with trastuzumab (+/− chemotherapy) 
due to possible additional toxicity and expected increased 
efficacy. For example, in the neoALTTO trial, a 1500 mg 
lapatinib dose was used for the lapatinib group but 1000 
mg was used when combined with trastuzumab [20]. To 
demonstrate the additive effect of the drug combination, 
we also used a lower dose of lapatinib, which did not 
reduce tumour size in this experiment (Fig 6A). The 
results in the pertuzumab treated group varied, with two 
tumour regressed but another two progressed. All tumours 
in the combination treatment group regressed and this 
change was significantly different from the vehicle group 
(p<0.05) and the lapatinib group (p<0.01). The above 
results suggested that the combination of lapatinib and 
pertuzumab outperformed either monotherapy in vivo. 
Immunohistochemistry staining was performed to 
detect all the HER receptors and their phosphorylated 
forms as well as the expression of Ki-67 and cleaved 
caspase-3 in the xenografted tumours. The tumours that 
received combination treatment expressed significantly 
higher levels of HER4 than all other treatment groups (p 
<0.05) (Fig. 6C). There was no significant difference in 
phospho-HER4 among all treatment groups (not shown); 
however, since the combination treatment group had 
high HER4 expression, the ratio of pHER4:HER4 in the 
combination group was significantly lower than that of 
the vehicle control group (p<0.05) (Fig. 6B). Although 
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trastuzumab has been shown to downregulate HER2 
[31], there was no decrease of HER2 level by lapatinib or 
pertuzumab or their combination in vivo (Suppl. Fig. 6). 
There were also no significant differences in other protein 
markers between the different groups (Suppl. Fig. 6).
The results of IHC staining were also compared 
with the regression status of the tumours. The regressed 
tumours had significantly reduced ratio of pEGFR:EGFR 
(p<0.05) (Fig. 6D) and pHER4:HER4 (p<0.001) (Fig. 6E) 
compared to the tumours without regression, suggesting 
the inhibition on EGFR and HER4 might be the cause of 
tumour regression. There was also higher expression of 
Figure 6: Anti-tumour effect of lapatinib/pertuzumab combination in vivo. (A) Mice bearing BT-474 xenograft were treated 
with the indicated treatments. (Lapatinib: 50 mg/kg five times per week; pertuzumab 12 mg/kg loading dose followed by 6 mg/kg 
maintenance dose per week). Tumour volume was measured three times a week (as indicated at each data point) for 22 days. The tumour 
volume was normalised to the tumour volume on day 0. (B-E) Indicated HER receptors and their phosphorylated forms (shown in the ratio 
of phosphorylated:total receptor) were scored in terms of IHC staining intensity and percentage of cells. The scores were then grouped 
according to (B and C) the treatments that the mice received or (D and E) tumour regression status. (Error = SD; *p<0.05, **p<0.01, 
***p<0.001).
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HER4 in the regressed tumours (p<0.05), but there were 
no significant differences between regressed and non-
regressed tumours in other proteins (Suppl. Fig. 7).
DISCUSSION
NRG1 has been implicated in lapatinib resistance 
[27] as well as overcoming the inhibitory effect of 
gefitinib [32] and trastuzumab [33] treatment in 
HER2-overexpressing breast cancer cells. Our study 
demonstrated that the NRG1 protein expression levels 
increased in response to lapatinib treatment in HER2-
overexpressing breast cancer cell lines, and lapatinib could 
not sustain its inhibition of HER receptor signalling. The 
use of SPG1 antibody suggested that HER3 ligands may 
contribute to lapatinib resistance. Moreover, we showed 
that pertuzumab could enhance response to lapatinib in 
BT-474 cells and xenograft models. 
A very recent study revealed that high NRG1 
expression predicts a decreased recurrence-free survival 
in HER2-overexpressing breast cancer patients compared 
to patients with low NRG1 expression [27], suggesting 
the clinical importance of NRG1. Although their study 
aimed to demonstrate the role of NRG1 autocrine 
signalling in the acquired lapatinib resistance, they 
combined the data of all patients receiving chemotherapy, 
tamoxifen or systematically untreated; therefore, this 
analysis could not address the association between 
NRG1 expression and lapatinib response. To date, there 
is only one published clinical trial involving lapatinib 
(EGF104911) that measured NRG1 level in tumours by 
immunohistochemistry (IHC), but they did not mention 
any correlation between NRG1 and clinical benefits 
from lapatinib monotherapy [34]. We propose for further 
studies to be done to validate NRG1 as a predictive 
biomarker for lapatinib sensitivity. Since ADAM10 and 
17 have been shown to play a role in mediating acquired 
resistance to trastuzumab through the shedding of HER 
ligands [33, 35], it may be important to assess the role of 
ADAM 10 and 17 proteases as well as other HER ligands 
in mediating lapatinib resistance in HER2-positive breast 
cancer.
The addition of pertuzumab to lapatinib inhibited 
the phosphorylation of HER3 and HER4, suggesting that 
HER3 and HER4 still preferentially bind to HER2 even in 
the presence of lapatinib. However, the phosphorylation of 
downstream MAPK and Akt was not completely inhibited. 
This may be caused by the residue kinase activity of the 
HER receptors, or the dimerisation of HER3 and HER4 
with EGFR or each other. Thus, it may be important to 
assess the different dimerisation patterns in relation to 
lapatinib treatment and resistance [36]. Since neratinib 
could overcome trastuzumab resistance [37] and lapatinib 
resistance [27], it will be interesting to assess whether 
the combination of pertuzumab and neratinib will also 
be additive in vitro and in vivo for HER2-positive breast 
cancer. 
HER4 expression levels were high in the tumours 
treated with the combination of lapatinib and pertuzumab, 
suggesting HER4 may mediate the effect of the drugs 
on tumour regression. HER4 has been implicated in 
both favourable and poor prognosis [38], but the cellular 
functions of HER4 vary among different isoforms as well 
as its localisation [39]. Our lab has previously shown 
that HER4 cleavage and nuclear translocation mediates 
acquired resistance to trastuzumab; and nuclear HER4 but 
not cytoplasmic HER4 is associated with poor outcome 
in HER2-positive breast cancer [40]. Therefore, further 
analysis of HER4 isoforms as well as its proteolytic 
cleavage and localisation may be required to understand 
the correlation of HER4 expression and lapatinib-induced 
tumour regression. There was no significant difference in 
the expression of Ki-67 and cleaved caspase-3 between 
the combination group and other different treatment 
groups in the BT-474 xenograft experiment, although the 
combination group was the most effective in inhibiting 
tumour growth. This could be because the analysed 
tumours are the residual tumour cells that were either 
innately resistant or had developed acquired resistance to 
the treatment(s). There is also a possibility that the tumour 
regression may not be caused by the difference in growth 
rate or apoptosis between the groups. The other potential 
mechanisms to consider include vessel growth inhibition, 
changes in vessel perfusion and ADCC which could be 
induced by pertuzumab [41].
Total cell counting and apoptotic assays showed that 
SK250LR cell line was not sensitive to the combination 
treatment of lapatinib and pertuzumab. The innate 
resistance to pertuzumab may be due to the permanent 
change in cell biology such that they are no longer 
dependent on EGFR and HER2 signalling. However, the 
BT250LR cell line was still dependent on HER2 signalling 
and responded to pertuzumab treatment. Our data shows 
that the combination of lapatinib and pertuzumab or 
pertuzumab alone may be effective in a subset of lapatinib-
resistant cancers, which could be further confirmed in vivo 
by testing in a BT250LR xenograft model. 
One limitation of our study was that it was 
carried out in only two cell lines, SK-BR-3 and BT-
474, although the lapatinib-resistant variants of these 2 
cell lines were included. These two cell lines appeared 
to have different mechanisms of acquired resistance to 
lapatinib. Therefore, more acquired lapatinib-resistant 
cell lines could be generated from other lapatinib-
sensitive HER2-overexpressing breast cancer cell lines to 
further understand the difference mechanisms of acquired 
lapatinib resistance. A recent report showed that anti-
HER3 monoclonal antibody was synergistic with lapatinib 
in PC9ZD, a gefitinib-resistant lung cancer cell line which 
harbours the T790M mutation [42]. As we have shown 
that the NRG1/HER3 pathway was one of the mechanisms 
of acquired lapatinib resistance in HER2-overexpressing 
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breast cancer cell lines, this pathway might also have 
a potential role in breast cancer cells that have innate 
resistance to lapatinib. Thus, it would be important to 
assess the role of HER3 ligands and the effect of HER3 
monoclonal antibodies in combination with lapatinib in 
a larger panel of lapatinib-sensitive and innate-resistant 
breast cancer cell lines. 
It may also be important to consider other pathways 
which may affect HER receptor signalling and lapatinib 
sensitivity. For example, a recent report showed that 
neurotensin (NTS) and its high affinity receptor (NTSR1) 
enhances EGFR, HER2, and HER3 activation, but 
lapatinib could reduce the tumour growth of breast cancer 
cells overexpressing NTS and NTSR1 [43]. Therefore, 
it could be interesting to further assess the cross-talk 
between neurotensinergic and the HER pathways in 
relation to lapatinib sensitivity and resistance. It may also 
be useful to use a high-throughput combinatorial drug 
screening approach to identify compensatory pathways 
that mediate lapatinib resistance and to target them with 
other targeted agents in combination with lapatinib to 
overcome its resistance and to achieve durable clinical in 
order benefit [44]. 
Although lapatinib plus pertuzumab may be a 
useful combination strategy for anti-HER2 therapy, it 
will require further comparison with trastuzumab plus 
pertuzumab or trastuzumab plus lapatinib or the triple 
combination in preclinical models and in future human 
patient trials. Furthermore, since this study was initiated, 
the roadmap for anti-HER2 treatments has changed. For 
metastatic breast cancer, the combination of pertuzumab 
and trastuzumab with docetaxel chemotherapy is now 
recommended as the first-line treatment. T-DM1 is 
increasingly used as the second-line anti-HER2 treatment 
since EMILIA trial showed that T-DM1 was superior to 
lapatinib plus capecitabine in prolonging progression-free 
and overall survivals, and it caused less toxicity in HER2-
positive breast cancer patients previously treated with 
trastuzumab and a taxane [45]. This means that lapatinib 
with capecitabine is increasingly being used as a third-
line anti-HER2 treatment for metastatic breast cancer. 
Although we showed that pertuzumab and lapatinib could 
potentially be useful in the setting of lapatinib resistance, 
this is uncertain in the context of patients who have 
previously failed three lines of anti-HER2 treatments, 
namely pertuzumab and trastuzumab with docetaxel 
followed by T-DM1 and lapatinib with capecitabine. This 
will needs to be tested in preclinical models first. However, 
the combination may still be potentially useful for patients 
who have started on lapatinib containing regimen first and 
have not had pertuzumab.
In summary, we have found that lapatinib could 
not sustain the inhibition of HER receptor signalling. 
This is correlated with an increased upregulation of 
NRG1 expression in HER2-overexpressing cells. Both 
the parental and lapatinib-resistant SK-BR-3 and BT-474 
cells were sensitive to SGP1, which inhibits the binding 
of NRG1 and other HER3 ligands. The exogenous NRG1 
stimulation diminished the inhibitory effect of lapatinib in 
HER2-overexpressing cells. The addition of pertuzumab 
to lapatinib inhibited NRG1-stimulated HER3 and HER4 
signalling in both SK-BR-3 and BT-474 cells, although the 
additive effect was only seen in the parental and resistant 
BT-474 cells as well as BT-474 xenograft models. This 
novel combination treatment may provide a promising 
strategy in clinical HER2-targeted therapy and may inhibit 
a subset of lapatinib-resistant breast cancer, although the 
group of patients that will respond to this therapy requires 
further stratification.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer cell lines SK-BR-3 and 
BT-474 were obtained from cell services at Cancer 
Research UK (Lincoln’s Inn Fields laboratory), which 
has a stringent quality control in cell authenticity and has 
incorporated short-tandem repeat (STR) profiling for cell 
line validation. Lapatinib-resistant cell lines SK250LR 
and BT250LR were generated by chronic exposure of 
increasing concentration of lapatinib from 25 nM, 50 
nM, 100 nM to 250 nM for 10 months, then the cells 
were maintained in 250 nM lapatinib. Fresh lapatinib 
was replaced every 3 days. Lapatinib was purchased from 
Selleck Chemicals. Pertuzumab was generously provided 
by Roche. SGP1 antibody was obtained from Cancer 
Research Technology.
Recombinant NRG1 was obtained from Sigma-
Aldrich. Human non-specific IgG control was purchased 
from R&D Systems.
SDS-PAGE and Western blotting
The procedures of SDS-PAGE and Western 
blotting have been previously described [33, 35]. Primary 
antibodies to EGFR (1:5000), phospho-HER2 (Y1221/22) 
(1:1000), HER2 (1:10000), phospho-HER3 (Y1289) 
(1:1000), HER3 (1:10000), phospho-Akt1/2 (S473) 
(1:1000), Akt1/2 (1:5000), phospho-p42/44-MAPK 
(T202/Y204) (1:1000), p42/44-MAPK (1:5000) and 
β-actin (1:2500) were from Cell Signalling Technology. 
Antibodies recognising phospho-EGFR (Y1173) (1:1000) 
and phospho-HER4 (Y1056) (1:1000) were obtained from 
Santa Cruz Biotechnology. Anti-HER3 (1:10000) antibody 
was purchased from Abcam. HRP-conjugated anti-
rabbit IgG secondary antibody (1:10000) was purchased 
from Life Technologies. After antibody incubation, the 
membrane was visualised using ImageQuant LAS 4000 
mini system (GE healthcare).
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ELISA
ELISA detection of NRG1 was performed using the 
Human NRG1-β1/HRG1-β1 DuoSet kit (R&D Systems) 
and the procedures were done according to manufacturer’s 
protocol. A six-point standard curve was produced using 
a 2-fold serial dilution of a standard of 4000 pg/ml NRG1 
and plotted using a fourth order polynomial function in 
GraphPad Prism 6. The concentration of NRG1 in each 
sample was calculated using the standard curve and 
normalised with the protein concentration as a surrogate 
for cell number.
RNA silencing
AllStars Negative Control (Qiagen) 
was used as scramble siRNA. siNRG1-9 
(5′-UUUCAAACCCCUCGAGAUA-3′) and siNRG1-11 
(5′-GGGGAGUGCUUCAUGGUGA-3′) were 
designed by Thermo Scientific and synthesised by Life 
Technologies. siRNA was diluted in Opti-MEM medium 
to the final concentration as indicated in the experiments 
for each reaction. DharmaFECT 1 Transfection Reagent 
was diluted in Opti-MEM medium (5 μl reagent in 15 
μl medium for each reaction) and incubated at RT for 5 
minutes. Diluted siRNA was mixed with the DharmaFECT 
1 solution and then incubated at RT for another 20 minutes. 
Cells maintained in antibiotics-free medium supplemented 
with 10% FBS were seeded on a 6-well plate with the 
DharmaFECT 1-siRNA complexes. The culture medium 
was replaced 24 hours post-transfection. 
Quantitative PCR
RNA was isolated from cells using RNeasy mini 
kit (Qiagen) according to manufacturer’s protocol. cDNA 
was synthesised using the High-Capacity cDNA Reverse 
Transcription kit (Life technologies). Quantitative 
PCR were performed using the following primers, 
together with SensiMix SYBR Hi-ROX kit (Bioline): 
NRG1, 5′-GCTTCATGGTGAAAGACCTTTCA-3′ 
and 5′-ATTACGTAGTTTTGGCAGCGATC-3′; 
β-actin, 5′-ATTGGCAATGAGCGGTTC-3′ and 
5′-GGATGCCACAGGACTCCAT-3′. Triplicate of the 
cDNA sample were analysed using Applied Biosystems 
7900HT Fast Real-Time PCR System.
Real-time live cell imaging
Approximately 10,000 cells per well (for SK-BR-3 
and SK250LR) or 20,000 cells per well (for BT-474 and 
BT250LR) were seeded in triplicate on 24-well tissue 
culture plates (Essen BioScience), allowed to adhere and 
enter log phase overnight. Each triplicate was treated with 
the indicated agents. Cell proliferation was monitored 
by IncuCyte Kinetic Live Cell Imaging System (Essen 
BioScience). High quality phase-contrast images of 16 
fields in each well were taken in 6-hour interval for 4 
days (SK-BR-3 and SK250LR) or 7 days (BT-474 and 
BT250LR). Culture medium and drugs were replaced on 
day 2 and day 5. The metric of monolayer confluence was 
measured by IncuCyte software package Confluence v1.5 
and used as a surrogate for cell number. The growth rate 
of cells was calculated by plotting the log of confluence 
against time. The percentage growth rate is calculated with 
respect to DMSO control.
Cell proliferation assay
Approximately 10,000 cells per well (for SK-BR-3 
and SK250LR) or 20,000 cells per well (for BT-474 and 
BT250LR) were seeded in triplicate on 24-well tissue 
culture plates, allowed to adhere and enter log phrase 
overnight. Each triplicate was treated with the indicated 
agents for 3 days. Culture medium was discarded. Cells 
were washed with PBSA twice and then detached from 
the well with 500 μl of 0.25% trypsin-EDTA solution. 
Trypsinised cells were diluted using Coulter Isoton II 
diluent and counted using a Coulter Z2 particle counter 
(Beckman Coulter); only the cell population with the size 
of 13–27 μm was counted.
Apoptotic assay
Approximately 150,000 cells per well were seeded 
on 6-well tissue culture plates, allowed to adhere and 
enter log phrase overnight. Each well was treated with 
the indicated agents for 2 days. Culture medium was 
collected. The cells were washed twice with PBSA and 
the PBSA was retained to collect non-adhered cells. The 
cells were trypsinised, washed and resuspended with their 
respective culture medium-PBSA mixture. Along with the 
non-adhered cells, cells were pelleted and washed with 
PBSA twice. The washed cell pellet was then resuspended 
in Annexin V-Alexa Fluor 647 (Life Technologies) and 
propidium iodide (Sigma-Aldrich) solution, and incubated 
in the dark at RT for 15 minutes. The stained cells were 
analysed using a CyAn ADP analyser (Beckman Coulter). 
AV-Alexa Fluor 647 was measured by excitation at 642 
nm and emission detection at 665 nm. Propidium iodide 
(PI) was measured by excitation at 405 nm and emission 
detection at 675 nm.
Xenograft experiment
BalB/c-nude mice were purchased from Charles 
River. All protocols were carried out with appropriate 
ethical approval under Home Office regulations and the 
Oncotarget5690www.impactjournals.com/oncotarget
project license of Dr. Ji-Liang Li (PPL 30/2771) as per 
previous xenograft experiment [46]. At the age of 5–6 
weeks, approximately 5×106 BT-474 cells in 1:1 matrigel/
RPMI 1640 medium were injected subcutaneously 
into the mammary fat pad of the mice under general 
anaesthesia induced by isoflurane. The diet of the mice 
was supplement by 5ug/ml β-estradiol and 0.04% (v/v) 
Baytril in drinking water from 2 days before tumour cell 
implantation until the end of experiment. The xenograft 
tumour size was monitored twice a week before treatment. 
When the tumour size of more than 40% of mice reached 
100–150 mm3 (length×width×height×0.52), the mice 
were randomised into 4 treatment groups: a) TWEEN80 
(control for lapatinib) and PBSA (control for pertuzumab), 
b) lapatinib and PBSA, c) TWEEN80 and pertuzumab, d) 
lapatinib and pertuzumab, and they received treatment for 
3 weeks. Lapatinib was administered 5 times per week at 
50 mg/kg body weight, half of the standard dose [47, 48], 
by oral gavage. Pertuzumab was administered once per 
week at 12mg/kg body weight for the first week and 6mg/
kg body weight afterwards by intraperitoneal injection [49, 
50]. The mice were sacrified when the geometric mean 
diameter ([length + width]÷2) of the tumour exceeded 15 
mm or animal welfare was compromised. The mice were 
euthanised by cardiac puncture under isoflurane general 
anaesthesia and death confirmed by neck dislocation. 
Residual tumours were removed and were immediately 
fixed in 4% paraformaldehyde at 4°C for 48 hours and 
stored in 70% ethanol at 4°C until being processed at the 
Oxford Centre for Histopathology Research. Paraffin-
embedded tumours were sectioned into 4 µm slides.
Immunohistochemistry staining
The tissue sections were incubated at 60°C for 
10 minutes and then were immediately washed twice in 
histo-clear solution (National Diagnostics) for 5 minutes 
each. Then they were rehydrated twice with 100% ethanol 
for another 5 minutes each, followed by 70% ethanol 
for 5 minutes and finally tap water for 5 minutes. The 
rehydrated tissue sections were put in a vessel containing 
1× Target retrieval solution (Dako) or EDTA pH8.0 buffer 
(according to antibody manufacturer’s protocol). The 
vessel was heated to 125°C for 2 minutes in a pressure 
cooker. Once the cooker de-pressurised, the tissue sections 
were rinsed in water and kept in PBS until blocking. The 
samples were blocked with normal horse serum (available 
from ImmPRESS kit, Vector Laboratories) at RT for 30 
minutes. Primary antibodies diluted in normal horse serum 
were applied to the slides and incubated at 4°C overnight. 
The tissue sections were washed in PBS for 5 minutes. 
Mouse or rabbit secondary antibodies (available from 
ImmPRESS kit, Vector Laboratories) were applied and 
incubated at RT for 30 minutes. The tissue sections were 
washed in PBS for 5 minutes. ImmPACT DAB peroxidase 
substrate (Vector Laboratories) was diluted according to 
the manufacturer’s protocol and applied to the slides for 
1 to 10 minutes (depending on the antibody used), then 
washed with tap water. Haematoxylin (Sigma-Aldrich) 
counterstain was applied to the tissue sections for 30 
seconds and then washed with tap water. Finally, the tissue 
sections were mounted with Aquatex agent (VWR).
Primary antibodies for EGFR (1:50), phospho-
HER2 (Y1221/22) (1:320), HER2 (1:400) and phospho-
HER3 (1:1600) were obtained from Cell Signaling 
Technology. Phospho-EGFR antibody (1:50) was obtained 
from Santa Cruz Biotechnology. HER3 antibody (1:1000) 
was obtained from Abcam. Phospho-HER4 antibody 
(1:100) was obtained from Novus Biologicals. HER4 
antibody (1:200) was obtained from Thermo Scientific. 
Scoring of IHC staining was performed independently by 
two authors, WL and IR, based on the intensity of staining 
and the percentage of cells stained with a particular 
intensity. The score of each intensity band was calculated 
by multiplying the intensity score with the percentage 
of cells in such intensity (e.g. if 20% of cells have 3+ 
intensity, the score of would be 60). The total score of 
a sample is the sum of the scores of individual intensity 
bands; for example, a tumour sample, which has 60% of 
tumour cell with strong (3+) intensity, 20% of cells with 
moderate (2+) intensity and 20% of cells with weak (1+) 
intensity, has a total score of 3×60 + 2×20 + 1×20 = 240. 
The maximum score of a sample is 300 and the minimum 
is 0.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6. For experiments involving multiple treatment 
groups and technical replicates (e.g. total cell counting 
and ELISA), the data were analysed using matched 
two-way ANOVA with Bonferroni post-hoc correction. 
For experiments involving multiple treatments without 
technical replicates (e.g. western blot densitometry and 
FACS), the data were analysed using matched one-way 
ANOVA with Bonferroni post-hoc correction. To compare 
dose-dependent effect on different groups (e.g. lapatinib-
sensitive and -resistant cell lines), the parameters of the 
best-fit line/curve were compared using extra sum-of 
-squares F test. Comparison of two groups (regression vs. 
non-regression) was performed using unpaired t-test.
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